Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Background Current standard of care for metastatic castration-sensitive prostate cancer
supplements androgen deprivation therapy with either docetaxel, second-generation …

PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal
disease with current standard-of-care therapies. Homologous recombination repair (HRR) …

Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …

Summary Background The PI3K/AKT and androgen-receptor pathways are dysregulated in
metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN …

Background In the interim analyses of the LATITUDE study, the addition of abiraterone
acetate plus prednisone to androgen deprivation therapy (ADT) led to a significant …

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

Background Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus
prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the …

Prostate cancer is the most commonly diagnosed cancer affecting men in the United States.
The prostate is a hormone-dependent gland in which androgen hormones testosterone and …